|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAJC17 |
Gene summary for DNAJC17 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAJC17 | Gene ID | 55192 |
| Gene name | DnaJ heat shock protein family (Hsp40) member C17 | |
| Gene Alias | DNAJC17 | |
| Cytomap | 15q15.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9NVM6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55192 | DNAJC17 | LZE4T | Human | Esophagus | ESCC | 3.55e-02 | 1.33e-01 | 0.0811 |
| 55192 | DNAJC17 | LZE5T | Human | Esophagus | ESCC | 4.63e-02 | 2.83e-01 | 0.0514 |
| 55192 | DNAJC17 | LZE7T | Human | Esophagus | ESCC | 3.27e-02 | 1.16e-01 | 0.0667 |
| 55192 | DNAJC17 | LZE8T | Human | Esophagus | ESCC | 9.16e-04 | 2.07e-01 | 0.067 |
| 55192 | DNAJC17 | LZE24T | Human | Esophagus | ESCC | 6.85e-04 | 9.16e-02 | 0.0596 |
| 55192 | DNAJC17 | P1T-E | Human | Esophagus | ESCC | 2.42e-07 | 4.31e-01 | 0.0875 |
| 55192 | DNAJC17 | P2T-E | Human | Esophagus | ESCC | 5.17e-12 | 1.06e-01 | 0.1177 |
| 55192 | DNAJC17 | P4T-E | Human | Esophagus | ESCC | 1.06e-09 | 2.25e-01 | 0.1323 |
| 55192 | DNAJC17 | P5T-E | Human | Esophagus | ESCC | 1.78e-13 | 1.70e-01 | 0.1327 |
| 55192 | DNAJC17 | P8T-E | Human | Esophagus | ESCC | 1.52e-18 | 3.46e-01 | 0.0889 |
| 55192 | DNAJC17 | P9T-E | Human | Esophagus | ESCC | 3.17e-06 | 2.11e-01 | 0.1131 |
| 55192 | DNAJC17 | P10T-E | Human | Esophagus | ESCC | 8.14e-19 | 2.37e-01 | 0.116 |
| 55192 | DNAJC17 | P12T-E | Human | Esophagus | ESCC | 1.29e-20 | 3.14e-01 | 0.1122 |
| 55192 | DNAJC17 | P15T-E | Human | Esophagus | ESCC | 4.03e-06 | 2.16e-01 | 0.1149 |
| 55192 | DNAJC17 | P16T-E | Human | Esophagus | ESCC | 1.68e-13 | 2.32e-01 | 0.1153 |
| 55192 | DNAJC17 | P17T-E | Human | Esophagus | ESCC | 9.01e-04 | 2.05e-01 | 0.1278 |
| 55192 | DNAJC17 | P20T-E | Human | Esophagus | ESCC | 1.67e-07 | 1.59e-01 | 0.1124 |
| 55192 | DNAJC17 | P21T-E | Human | Esophagus | ESCC | 1.40e-18 | 3.19e-01 | 0.1617 |
| 55192 | DNAJC17 | P22T-E | Human | Esophagus | ESCC | 3.46e-11 | 1.89e-01 | 0.1236 |
| 55192 | DNAJC17 | P23T-E | Human | Esophagus | ESCC | 8.25e-11 | 2.77e-01 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:19019987 | Esophagus | ESCC | toxin transport | 28/8552 | 40/18723 | 1.61e-03 | 7.50e-03 | 28 |
| GO:19019986 | Oral cavity | OSCC | toxin transport | 25/7305 | 40/18723 | 2.22e-03 | 1.00e-02 | 25 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAJC17 | SNV | Missense_Mutation | novel | c.397N>A | p.Glu133Lys | p.E133K | Q9NVM6 | protein_coding | tolerated(0.44) | benign(0.026) | TCGA-DS-A7WH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DNAJC17 | SNV | Missense_Mutation | rs775459475 | c.763N>A | p.Val255Met | p.V255M | Q9NVM6 | protein_coding | tolerated(0.23) | benign(0.007) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNAJC17 | SNV | Missense_Mutation | c.613C>A | p.Leu205Ile | p.L205I | Q9NVM6 | protein_coding | tolerated(0.12) | benign(0.438) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| DNAJC17 | SNV | Missense_Mutation | rs774713452 | c.451N>T | p.Arg151Cys | p.R151C | Q9NVM6 | protein_coding | deleterious(0.03) | possibly_damaging(0.794) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| DNAJC17 | SNV | Missense_Mutation | rs148284868 | c.587N>A | p.Arg196Gln | p.R196Q | Q9NVM6 | protein_coding | tolerated(0.67) | benign(0.007) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNAJC17 | SNV | Missense_Mutation | c.490N>C | p.Asn164His | p.N164H | Q9NVM6 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DNAJC17 | SNV | Missense_Mutation | c.74N>G | p.Lys25Arg | p.K25R | Q9NVM6 | protein_coding | deleterious(0.04) | benign(0.114) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DNAJC17 | SNV | Missense_Mutation | rs529115513 | c.419N>G | p.Glu140Gly | p.E140G | Q9NVM6 | protein_coding | deleterious(0) | benign(0.006) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DNAJC17 | SNV | Missense_Mutation | rs148284868 | c.587N>A | p.Arg196Gln | p.R196Q | Q9NVM6 | protein_coding | tolerated(0.67) | benign(0.007) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| DNAJC17 | SNV | Missense_Mutation | novel | c.238N>C | p.Lys80Gln | p.K80Q | Q9NVM6 | protein_coding | deleterious(0.02) | benign(0.206) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |